A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D

医学 内科学 入射(几何) 丁型肝炎 丁型肝炎病毒 胃肠病学 病毒学 相(物质) 乙型肝炎表面抗原 肝炎 核糖核酸 临床试验 临床研究阶段 免疫学 丙型肝炎
作者
Tarik Asselah,Michael A. Chattergoon,Alina Jucov,Anca Streinu‐Cercel,Pietro Lampertico,Heiner H. Wedemeyer,Patrick T.F. Kennedy,Edward John Gane,Brianna L. Bullard,Sophia Chow,Desiree Santos,Grégory Camus,Yimeng Lu,Cara Pilowa,Carey K. Hwang,Todd A. Correll,Kosh Agarwal
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:394 (4): 343-353 被引量:31
标识
DOI:10.1056/nejmoa2508827
摘要

BACKGROUND: Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D virus (HDV) infection are unknown. METHODS: IU per milliliter from baseline (virologic response) and normalization of the alanine aminotransferase (ALT) level, at week 24. RESULTS: At week 24, a combined response was observed in 47% of participants (15 of 32) who received tobevibart plus elebsiran and in 70% of participants (23 of 33) who received tobevibart, with a virologic response in 100% (32 of 32) and 82% (27 of 33), respectively, and normalization of the ALT level in 47% (15 of 32) and 76% (25 of 33). At week 48, a combined response was observed in 56% of participants (18 of 32) with tobevibart plus elebsiran and 61% of participants (20 of 33) with tobevibart; undetectable HDV RNA (also known as target not detected, or TND; no amplification during reverse-transcriptase-polymerase-chain-reaction assay) in 66% (21 of 32) and 48% (16 of 33), respectively; normalization of the ALT level in 56% (18 of 32) and 61% (20 of 33); and an HBsAg level below 10 IU per milliliter in 91% (29 of 32) and 21% (7 of 33). No ALT flares were observed in participants starting tobevibart and elebsiran simultaneously or receiving tobevibart monotherapy. Through week 48, a total of 81% of participants who received tobevibart plus elebsiran and 94% of those who received tobevibart had at least one adverse event, primarily influenza-like illness and chills. CONCLUSIONS: In this phase 2 trial, tobevibart plus elebsiran as well as tobevibart monotherapy decreased HDV RNA and ALT levels through week 48. Treatment with tobevibart plus elebsiran was associated with a high incidence of undetectable HDV RNA and of a decrease in the HBsAg level. (Funded by Vir Biotechnology; ClinicalTrials.gov number, NCT05461170.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
入司的应助被乐鱼采纳,获得10
刚刚
刚刚
33LL发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
2秒前
充电宝的应助被zhuluosheng采纳,获得10
2秒前
小红完成签到,获得积分10
3秒前
赵玉珊发布了新的文献求助10
3秒前
3秒前
4秒前
小马甲的应助被子岚采纳,获得10
4秒前
13发布了新的文献求助10
4秒前
orixero的应助被大气大侠采纳,获得10
4秒前
俊逸鸣凤发布了新的文献求助10
4秒前
4秒前
4秒前
5秒前
哈哈哈发布了新的文献求助10
5秒前
5秒前
科研全白的应助被柯科研采纳,获得10
5秒前
Lzn发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
6秒前
6秒前
6秒前
科研通AI6.3的应助被高速公鹿采纳,获得10
6秒前
藤藤菜的应助被hongyi采纳,获得100
7秒前
7秒前
7秒前
郑睿涛发布了新的文献求助10
7秒前
王韩旭发布了新的文献求助10
7秒前
7秒前
无极微光的应助被Zoey Young采纳,获得20
7秒前
Lenna45完成签到 ,获得积分10
7秒前
8秒前
海棠发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182914
求助须知:如何正确求助?哪些是违规求助? 9572166
关于积分的说明 21823466
捐赠科研通 7779489
什么是DOI,文献DOI怎么找? 3433733
关于科研通互助平台的介绍 2557961
邀请新用户注册赠送积分活动 2479897